Addex Therapeutics to Attend H.C. Wainwright Investment Conference
Geneva, Switzerland – Addex Therapeutics (SIX/NASDAQ: ADXN), a company focused on developing innovative small molecule allosteric modulators for neurological disorders, is pleased to announce that its CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference. This important event will take place at the Lotte New York Palace Hotel from September 9 to September 11, 2024.
Corporate Update Presentation
At the conference, attendees will have the opportunity to view a video presentation featuring Mr. Dyer, which will be available on-demand starting at 07:00 EDT on September 9, 2024. During this presentation, he will share updates on Addex's corporate progress and discuss recent developments, showcasing the company’s dedication to advancing treatments for neurological conditions.
One-on-One Meetings
Throughout the event, Tim Dyer will be available for one-on-one meetings, allowing stakeholders and interested parties to engage in detailed discussions about Addex's initiatives and advancements. If you would like to schedule a meeting, please contact the company using the information provided below.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company that is leading the way in developing a strong portfolio of allosteric modulators aimed at treating neurological disorders. Their top drug candidate, dipraglurant, is specifically designed as a negative allosteric modulator targeting the mGlu5 receptor and is currently being evaluated for its potential in aiding recovery from brain injuries, including strokes and traumatic brain injuries.
Collaborations and Future Developments
Addex has formed a partnership with Indivior to advance a GABAB PAM drug candidate tailored for treating substance use disorders, with plans to begin IND enabling studies in the first half of 2025. Furthermore, Addex is also independently progressing a GABAB PAM program focused on chronic cough, with intentions to initiate IND enabling studies in 2025.
Equity Interests and Other Projects
The company holds a 20% equity stake in Neurosterix LLC, which is advancing an exciting pipeline of allosteric modulator programs. These efforts include developing treatments for schizophrenia with an M4 PAM, addressing mood disorders with an mGlu7 NAM, and tackling mild neurocognitive disorders using an mGlu2 NAM. Addex's shares are publicly traded on both the SIX Swiss Exchange and the NASDAQ Capital Market under the ticker symbol ADXN.
Contact Information
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)20 7318 2955
Email: msinclair@halsin.com
Frequently Asked Questions
What is the H.C. Wainwright investment conference?
The H.C. Wainwright investment conference is an event where public companies share their business updates and opportunities with potential investors.
Who is the CEO of Addex Therapeutics?
Tim Dyer serves as the Chief Executive Officer of Addex Therapeutics.
What is Addex Therapeutics focused on?
Addex Therapeutics specializes in developing innovative small molecule allosteric modulators for the treatment of various neurological disorders.
What are some of Addex's lead drug candidates?
One of Addex's leading drug candidates is dipraglurant, which is aimed at facilitating recovery from brain injuries.
How can I contact Addex Therapeutics?
You can reach out to Addex Therapeutics via email at PR@addextherapeutics.com for any inquiries.
